Results.
In total, 19,681 patients were eligible for analysis in this study.
During an average follow-up of 15 years, the event rates of each
comorbidity differed significantly between the users and non-users of
biologics with regard to cardiovascular comorbidity, metabolic
comorbidity, rheumatologic comorbidity, and the miscellaneous
comorbidity (all p<0.05). The usage of biologic agents in RA
patients reduced the HR of cardiovascular comorbidities by 18%,
metabolic comorbidities by 17%, rheumatology comorbidities by 36%, and
miscellaneous comorbidities by 15% compared to those patients who did
not use biologics. Oncology comorbidities and infection comorbidities
were not affected by treatment with biologics (p>0.05).